



NVP-ACC789

Catalog No: tcsc0015997

Available Sizes
Size: 5mg
Size: 10mg
Size: 25mg
Size: 50mg
Specifications
CAS No: 300842-64-2
Formula: C ₂₁ H ₁₇ BrN ₄
Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK
Target: VEGFR;PDGFR
Purity / Grade: >98%
Solubility: DMSO: 60 mg/mL (148.04 mM; Need ultrasonic and warming)
Alternative Names: ACC-789;ZK202650
Observed Molecular Weight: 405.29





Product Description

NVP-ACC789 is an inhibitor of human **VEGFR-1**, **VEGFR-2** (mouse **VEGFR-2**), **VEGFR-3** and **PDGFR-\beta** with **IC**₅₀s of 0.38, 0.02 (0.23), 0.18, 1.4 μ M, respectively.

IC50 & Target: IC50: 0.38 μM (human VEGFR-1), 0.02 μM (human VEGFR-2), 0.23 μM (mouse VEGFR-2), 0.18 μM (human VEGFR-3), 1.4 μM (human PDGFR- β)^[1]

In Vitro: The enzymatic kinase assays demonstrate that NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR- β with IC $_{50}$ s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively. In VEGF-treated cultures, addition of the VEGFR-2 inhibitor NVP-ACC789 reduces BME cell number to baseline levels from 1 μM. Likewise, bFGF-induced BME cell proliferation is reduced markedly by NVP-ACC789 from 1 to 10 μM, without however reaching basal levels. NVP-ACC789 is found to be a potent inhibitor of VEGF-induced HUVE cell proliferation with an IC $_{50}$ of 1.6 nM. NVP-ACC789 also completely inhibits VEGF-induced BME and BAE cell invasion and VEGF-C-induced BAE cell invasion. The inhibition is dose-dependent in both cell types with a maximal effect from 1 μM^[1].

In Vivo: NVP-ACC789 which is given in daily oral doses for 6 days blocks VEGF-induced angiogenesis in a dose-dependent manner. NVP-ACC789 also inhibits the response to bFGF to some extent, but the dose-response curve is not linear for NVP-ACC789^[1].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!